Coherus Biosciences (CHRS) Stock Statistics & Valuation Metrics

Coherus Biosciences has a market cap or net worth of $102.11M. The enterprise value is $247.49M.

Coherus Biosciences has 115,933,270 shares outstanding. The number of shares has decreased by -2.65% in one year.

Coherus Biosciences’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is -66.77%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Coherus Biosciences had revenue of 266.96M and earned 28.51M in profits. Earnings per share was 0.25.

In the last 12 months, operating cash flow was 500.00K and capital expenditures 0.00, giving a free cash flow of 500.00K billion.

Coherus Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Coherus Biosciences upcoming earnings date is Jul 31, 2025, After Close (Confirmed).

Coherus Biosciences as a current ratio of 1.21, with Debt / Equity ratio of -126.14%

In the past 12 months, Coherus Biosciences has paid 0.00 in taxes.

Coherus Biosciences EV to EBITDA ratio is 4.96, with an EV/FCF ratio of -14.77.

Coherus Biosciences has $82.41M in cash and marketable securities with $231.42M in debt, giving a net cash position of $149.01M billion.

Gross margin is 55.52%, with operating margin of -41.83%, and net profit margin of 10.68%.

The average price target for Coherus Biosciences is $4.05, which is 11.43% higher than the current price. The consensus rating is Moderate Buy